Ucla cancer research

Across campusundergraduate researchgraduate researchresearch and entrepreneurshiplibrariesadministration ch centers & over 350 labs, centers and institutes, ucla provides extensive resources and information to its research resources — ranging from 290 medical research centers to institutes that focus solely on environmental sustainability and world languages — mean that for every research question, we have the ability to answer ch at the david geffen school of institute for neuroscience and human of dentistry n comprehensive cancer center of nursing ng school of public health te school of education and information samueli school of engineering and applied school of public affairs research sciences grant ute of the environment & for world policy ctive studentscurrent studentsfacultystaffalumniparents & ewchancellorleadershipmission & valuesfacts & figuresawards & honorshistoryimpact & accomplishmentsiconic & influential alumnirankingscenters & institutescareersclose (x). Across campusundergraduate researchgraduate researchresearch and entrepreneurshiplibrariesadministration ch centers & over 350 labs, centers and institutes, ucla provides extensive resources and information to its research resources — ranging from 290 medical research centers to institutes that focus solely on environmental sustainability and world languages — mean that for every research question, we have the ability to answer ch at the david geffen school of institute for neuroscience and human of dentistry n comprehensive cancer center of nursing ng school of public health te school of education and information samueli school of engineering and applied school of public affairs research sciences grant ute of the environment & for world policy healthmyuclahealthschool of r cancer cancer urology ric urology te cancer in prostate igators & pmental research enhancement g services ic diseases in ntly asked questions (faq). More about clinical r cancer research kidney cancer research male urology research pediatric urology research prostate cancer research spore in prostate cancer health services research clinical te cancer te cancer ch prostate ucla department of urology is committed to ongoing prostate cancer research in a quest to develop new treatments and cures for all urologic conditions, along with a commitment to educate and train the next generation of leading physicians and . Aronson has worked extensively in the field of nutrition and prostate cancer for the past 20 years and has multiple publications demonstrating anticancer effects of nutritional strategies. Aronson's research team has demonstrated anticancer effects of dietary fish in mouse models and human also maintains an active laboratory at ucla evaluating the biological effects of dietary fish providing omega-3 fatty acids on prostate cancer growth and evaluating biomarkers to be applied to clinical trials. Aronson is funded by the national institutes of health to research the role of dietary fish and low-fat diets for prostate cancer prevention and treatment. He has over 150 publications in peer-reviewed journals including the new england journal of medicine, the journal of clinical oncology, cancer research, and the journal of ultimate goal of his research program is to discover whole food approaches utilizing a healthy fish-based diet for the prevention and treatment of malignancies and to promote .

Belldegrun is internationally recognized in the field of surgical and medical management of urological cancers, designing and conducting large-scale clinical trials, and in the development of innovative therapies for patients with localized and metastatic kidney, bladder, and prostate cancer. Belldegrun’s research laboratory at ucla has been a pioneer in the fields of genetic cancer therapy, immunotherapy, cancer vaccines, and targeted molecular therapy for urological . Arie belldegrun's research focuses on targeted specific therapy and immunotherapy of kidney and prostate cancers. The enhanced gene expression of the resulting construct, combined with its tissue specificity and androgen responsiveness, provide the foundation for the development of tissue specific vectors for prostate cancer gene grun's laboratory also has studied the feasibility of isolating functional dentrictic cells from the peripheral blood of renal cell carcinoma patients and has compared their transduction efficiency using various methods of transferring gene markers into dentritic chin, m. Focused on bladder and prostate cancer, his research team studies how the immune system recognizes and modulates cancer growth, invasion, and t projects include understanding the mechanisms that distinct immune pathways use to regulate tumor growth and spread, which will be important in identifying targets for novel immune-based therapies. A second area is focused on understanding bladder cancer stem cells, which may be the origin of the cancer. Targeting the cancer stem cell population, the team is studying the molecular and genetic mechanisms and is developing a personalized therapy program for bladder cancer patients to match specific treatments with patients.

Isla garraway is the principal investigator of a basic science laboratory in the jonsson comprehensive cancer center. Understanding what role stem cells play in cancer tumor growth could prove to be monumental in developing future targeted therapies for prostate cancer . He spent two years as a robert wood johnson clinical scholar at rand and ucla, where he earned his mph. He is a translational population scientist who has authored numerous original articles, reports, reviews, and book chapters in urologic oncology and health services research. Litwin published the first validated quality-of-life instrument to track outcomes in men with prostate cancer and has been an international leader in this area. Litwin's research includes medical outcomes assessment, quality of care, health-related quality of life, epidemiology, costs and resource utilization, patient preferences, and health care access for malignant and benign diseases in . Litwin’s post-doctoral research fellows have held academic positions at institutions such as harvard, duke, columbia , vanderbilt, ucla, and the universities of michigan, virginia , and washington , as well as in japan , france , and the netherlands .

2001 he received the aua gold cystoscope for his foundational work in establishing the discipline of urological health services research. His work has been funded by the niddk, nci, department of defense, american cancer society, california department of public health, and other organizations. His current grants include an $80 million state-funded program involving prostate cancer care for low-income uninsured men in california , as well as a $17 million epidemiologic study of the burden of urologic diseases in america . He teaches in ucla’s schools of medicine and public health and practices urologic oncology at . Litwin’s research is currently funded by the california department of public health, national institutes of health, national cancer institute, the agency for healthcare research and quality and national institute of diabetes and digestive and kidney primary research interests of dr. Leonard marks include prostate imaging and targeted biopsy, along with active surveillance of prostate cancer. Of all the major cancers, prostate cancer is the only one that cannot be imaged in the organ of origin, while still curable.

The ultimate goal is the rational treatment of localized prostate cancer: early diagnosis and cure for those men who need to be cured and avoiding treatment in those men who wouldn’t benefit from new approach calls for a sophisticated mri to be performed in advance of prostate biopsy. Using techniques of diffusion-weighted imaging and dynamic contrast enhancement, in conjunction with a larger-than-usual magnet (3tesla), many prostate cancers can be visualized on mri images. Allan pantuck’s research programs focus on gene and immune therapies for gu cancer, molecular and genomic characterization of kidney cancer, and nutritional chemoprevention of prostate g has been received and work completed on a project to study chromosome 9p alterations in kidney cancer, a continuation of work started in dr. Pantuck’s nih-awarded k23 training grant, which ultimately led to publication of a manuscript in the journal cancer. Pantuck’s work on genetic and molecular characterization of kidney cancer will now continue with a recently funded grant, for which he is the pi, from the department of defense titled “early diagnosis of clear cell kidney cancer using vhl/hif pathway regulated circulating microrna,” which seeks to identify a novel panel of micrornas that are measurable in serum for the early diagnosis of kidney cancer. Pantuck will receive funding for an nsf sbir phase ii grant with the ucla momentum incubator spin-off fibron corporation, and will also serve as co-investigator on a recently funded, 5 year nih-funded r01 grant on prostate cancer ten years, dr. A clinical trial utilizing this gmp manufactured vaccine has been approved by the fda recombinant advisory committee, and toxicology studies are being completed in support of an ind application for an investigator initiated clinical trial to be performed at ucla.

Pantuck’s research is currently funded by the national institutes of health, department of defense and the national science reiter, md, . He is currently the principal investigator of ucla’s spore (specialized program in research excellence) program, a 12 million dollar multifaceted research program that strives to translate basic science advances in prostate cancer to the management of men with this disease. There are currently only 9 active spore programs in the united states , of which ucla’s is the only such program in california. Reiter’s own research focuses on four main areas: (1) the development of antibodies against prostate cancer proteins that can be used to treat prostate cancer (2) novel imaging technologies for prostate cancer, including radiolabeled antibodies for pet imaging and mri for local cancer imaging (3) the application of molecular markers to predict prostate cancer prognosis and for the personalization of therapy, and (4) the role of stem cells in prostate cancer. Reiter’s lab has gained international attention for its discovery of the psca (prostate stem cell antigen) gene and the development of antibodies against psca that have entered clinical trials for both the treatment and imaging of prostate (as well as pancreatic) cancer. Reiter has won numerous awards and honors, including the stop cancer young investigator award, the society for urologic oncology young investigator award, and election to the american society for clinical investigation. His work has been funded continuously for 14 years by the national cancer institute, the american cancer society, the department of defense, the new york academy of medicine, the margaret early trust and other funding w rettig, m.

Is an associate professor in the department of medicine, division of hematology-oncology, and the department of urology, and is the medical director of the prostate cancer program of the institute of urologic oncology at the david geffen school of medicine at ucla. Rettig completed internal medicine residency at the university of washington before going on to a hematology-oncology fellowship at a medical oncologist, he focuses on the management of genitourinary malignancies with a focused clinical emphasis on advanced prostate cancer. As the director of the clinical trials program in prostate cancer at ucla, he conducts multiple prostate cancer clinical trials that span the spectrum of the states of the disease: from neoadjuvant therapies to post-chemotherapy, castration-resistant disease. Rettig’s bench research program, which is funded by the nih, department of defense and the department of veterans affairs, is focused on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer and clear cell renal cell opher saigal, md, . Christopher saigal’s research is focused on the nexus of quality of care and trends in medical technology. The urologic diseases in america project, an ongoing, nih-funded research enterprise, evaluates quality, cost, and technology trends in major urologic conditions such as prostate, kidney and bladder cancer, as well as benign diseases such as benign prostatic hyperplasia and kidney stones. Other major research efforts involve finding ways to use technology to improve decision making for patients in the setting of localized prostate cancer.

Saigal also leads the ucla site for two national nci-funded trials to examine outcomes of care in men treated for localized prostate . Saigal’s research is currently funded by the national institutes of health, national cancer institute and the lance armstrong . Gang zeng’s ongoing research involves dendritic cell (dc)-targeting prostate and kidney cancer vaccines, as well as a+psa technology for improved prostate cancer diagnosis and risk tic cell (dc)-targeting prostate and kidney cancer vaccines: dc-based vaccines have shown encouraging results in treating castration resistant prostate cancer. More potent cancer vaccines capable of targeting immature dc in vivo and bypassing the ex vivo manipulations, are critically needed. This project addresses the immunological and anti-tumor effects of dc-targeting vaccines using the myc-cap prostate cancer and renca kidney cancer models. Psa technology for improved prostate cancer diagnosis and risk assessment:we have developed a novel multiplex assay that simultaneously measures auto-antibodies and psa in a single reaction (termed the a+psa assay). This new technology is being investigated for aiding prostate cancer diagnosis with reduced unnecessary biopsies as well for predicting lethal from indolent prostate cancers with reduced .

Zeng’s research is currently funded by the national institutes of health, american cancer society, neuberger berman foundation and the dr. Susan love breast cancer ibe to our videos on us on us to your google+ t with us on us on us on y broken ibe to our videos on us on us to your google+ t with us on us on us on in to healthmyuclahealthschool of r cancer cancer urology ric urology te cancer in prostate igators & pmental research enhancement g services ic diseases in ntly asked questions (faq). Susan love breast cancer ibe to our videos on us on us to your google+ t with us on us on us on y broken ibe to our videos on us on us to your google+ t with us on us on us on in to @on school of geffen school of ng school of public te school of education & information samueli school of engineering and applied alpert school of school of public of the arts and of theater, film and s and stories and progress from the centennial campaign brain cancer ucla brain cancer research center is focused on finding a cure and providing the very best care for brain tumor tating diseases require revolutionary breakthroughs in research and care. Ucla’s brain cancer research center physicians and scientists are driven every day to end the devastation these diseases can wreak on generations of cause is not hopeless. Our renowned faculty, researchers and physicians are working day and night to solve this crisis in human health. Linda liau, who has developed a personalized vaccine that doubles the survival time for patients with deadly brain cancer, and dr. Carol kruse, who introduced a treatment for breast cancer that has spread to the neurooncologists lead teams of experts to deliver personalized medicine for brain cancer patients and the best possible care in the nation.

Supporters are committed to finding a cure for brain dear friend allan hirschorn died far too young from brain cancer.... I want to help fund research to find a brain cancer ering stephen hulsy, he lost his battle with cancer much too early in his life....